Risk of diarrhoea due to Clostridium difficile during cefotaxime treatment. Cefotaxime compares favourably with other third generation cephalosporins.
作者信息
Rothschild E, Rauss A, Danan G
出版信息
BMJ. 1996 Mar 23;312(7033):778. doi: 10.1136/bmj.312.7033.778.
Abstract
摘要
相似文献
1
Risk of diarrhoea due to Clostridium difficile during cefotaxime treatment. Cefotaxime compares favourably with other third generation cephalosporins.头孢噻肟治疗期间艰难梭菌所致腹泻的风险。头孢噻肟与其他第三代头孢菌素相比具有优势。
BMJ. 1996 Mar 23;312(7033):778. doi: 10.1136/bmj.312.7033.778.
2
Risk of diarrhoea, Clostridium difficile and cefotaxime in the elderly.
Biomed Pharmacother. 1997;51(2):63-7. doi: 10.1016/s0753-3322(97)87728-1.
3
Risk of diarrhoea due to Clostridium difficile during cefotaxime treatment. Mortality due to C difficile colitis in elderly people has been underestimated.头孢噻肟治疗期间艰难梭菌所致腹泻的风险。老年人艰难梭菌结肠炎所致死亡率一直被低估。
BMJ. 1996 Mar 23;312(7033):778. doi: 10.1136/bmj.312.7033.778a.
4
Increased risk of diarrhoea caused by Clostridium difficile in elderly patients receiving cefotaxime.接受头孢噻肟治疗的老年患者感染艰难梭菌导致腹泻的风险增加。
BMJ. 1995 Nov 18;311(7016):1345-6. doi: 10.1136/bmj.311.7016.1345.
5
6
Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam.
Aliment Pharmacol Ther. 1998 Dec;12(12):1217-23. doi: 10.1046/j.1365-2036.1998.00428.x.
7
[Cephalosporins--a common cause of nosocomial Clostridium difficile diarrhea].[头孢菌素——医院获得性艰难梭菌腹泻的常见病因]
Lakartidningen. 1992 Jan 15;89(3):109-10.
8
[The Norrköping study. Cephalosporins are often the implicating factors in Clostridium difficile infections].[诺尔雪平研究。头孢菌素常常是艰难梭菌感染的诱发因素]
Lakartidningen. 1991 Oct 9;88(41):3374, 3377, 3379.
9
Cephalosporin-associated pseudomembranous colitis due to Clostridium difficile.艰难梭菌所致的头孢菌素相关性假膜性结肠炎
JAMA. 1979 Dec 14;242(24):2683-5.
10
Clostridium difficile induced colitis occurring during cefotaxime therapy.在头孢噻肟治疗期间发生的艰难梭菌诱导的结肠炎。
Ulster Med J. 1985 Apr;54(1):80-2.
引用本文的文献
1
Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.头孢噻肟。对其抗菌活性和药代动力学特性的重新评估，以及对其每日两次给药治疗轻至中度感染时的治疗效果的综述。
Drugs. 1997 Mar;53(3):483-510. doi: 10.2165/00003495-199753030-00009.
本文引用的文献
1
Diagnosis and management of Clostridium difficile infection.艰难梭菌感染的诊断与管理
BMJ. 1995 May 27;310(6991):1375-80. doi: 10.1136/bmj.310.6991.1375.
2
Increased risk of diarrhoea caused by Clostridium difficile in elderly patients receiving cefotaxime.接受头孢噻肟治疗的老年患者感染艰难梭菌导致腹泻的风险增加。
BMJ. 1995 Nov 18;311(7016):1345-6. doi: 10.1136/bmj.311.7016.1345.
3
Community-acquired pneumonia.社区获得性肺炎
N Engl J Med. 1995 Dec 14;333(24):1618-24. doi: 10.1056/NEJM199512143332408.
4
Comparative toxicities of third-generation cephalosporins.
Am J Med. 1985 Aug 9;79(2A):96-103. doi: 10.1016/0002-9343(85)90268-2.
5
Gram-positive superinfections following beta-lactam chemotherapy: the significance of the enterococcus.β-内酰胺类化疗后的革兰氏阳性菌二重感染：肠球菌的重要性
Infection. 1985;13 Suppl 1:S81-8. doi: 10.1007/BF01644225.
Zotero 插件